Cannara Biotech (LOVE) Investor presentation summary

Market position and growth

• Ranked as one of Canada's fastest-growing top-10 licensed producers, with a strong retail presence in 8 out of 10 provinces and 94% of retail stores.

• Achieved #1 market share in Quebec and #6 nationally, with 20 consecutive quarters of positive adjusted EBITDA and 14 quarters of positive operating cash flow.

• National retail sales grew 5% quarter-over-quarter in Q2 2026, reaching $55.7M.

• Retail market share increased to 4.4% nationally and 14.3% in Quebec in Q2 2026.

• Holds leading positions in several product categories, including #1 infused pre-roll, hash rosin, live rosin vape, CBD flower, and premium live resin vape.

Financial performance

• Q2 2026 gross revenue was $38.8M, up $1.1M from Q2 2025; YTD gross revenue reached $81.6M, up $8.0M year-over-year.

• Gross profit before fair value adjustments was $11.6M in Q2 2026, with a gross margin of 43%.

• Adjusted EBITDA for Q2 2026 was $6.0M, with a margin of 22%; YTD adjusted EBITDA was $14.9M.

• Operating cash flow improved to $2.9M in Q2 2026 and $10.9M YTD.

• Free cash flow turned positive YTD at $3.1M, with a margin of 5%.

Assets and production capacity

• Operates two Quebec-based mega facilities: Valleyfield (1M sq. ft., 24 grow rooms, 45,000 kg/year) and Farnham (605,000 sq. ft., 11 grow rooms, 5,000 kg/year).

• Valleyfield facility acquired for $27M, with expansion plans to reach 100,000 kg annualized capacity.

• Farnham facility generates over $3.8M in annual rental revenues from non-cannabis tenants.

• Total owned potential production capacity is 100,000 kg annually, with phased room activations aligned to demand.